TIGIT and neoplasm: In addition to the typical expression of CD25, CD4, and FOXP3, Treg cells express a number of chemokine receptors and surface molecules, such as CTLA4, PD-1, and TIGIT, which are linked to anti-tumor immunity and may make them a direct target for ICI therapy.